Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

ESMO Virtual 2020: Impact of immunotherapy on quality of life

In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO.  During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]

read more

Sapanisertib is tolerable and shows activity in advanced kidney cancer

In a phase I study to look at the safety and tolerability of a new drug called sapanisertib, sapanisertib was well-tolerated and showed some anti-tumour activity in patients with renal cell carcinoma (RCC) and endometrial cancer. Sapanisertib is an oral, highly selective inhibitor of the mTORC1/mTORC2 receptors in advanced solid tumours. In the study, 82 […]

read more

Patients ‘left in the dark’ by the NHS over cancer treatments

Macmillan Cancer Support has recently published the results from their annual Cancer Patient Experience Survey, which reveals that around 120,000 cancer patients a year feel that topics, such as treatments and side effects, were not fully explained to them by NHS staff. This made them feel “left in the dark” by the NHS. Thirty-nine percent […]

read more

Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC). Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, […]

read more

Monitoring treatment toxicities in patients with renal cell carcinoma

Drs Dan George and Tian Zhang from the Duke Prostate and Urologic Cancer Centre, Durham, USA, share their views on monitoring side effects to treatment of patients with renal cell carcinoma (RCC). Emphasis is placed on counselling patients on expectations and managing baseline co-morbidities. Maintaining a prescribed treatment schedule while focused on quality of life […]

read more

Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

ESMO 2019: Neurologic complications of immunotherapy

This interview with Dr Matthias Preusser from the Medical University of Vienna, Austria discusses the neurologic side effects associated with the use of immunotherapy for the treatment of cancer.  The use of immunotherapy for the treatment of cancer has become routine and many cancer patients are being treated with these drugs. Side effects to immunotherapy can […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more
Showing 1 to 10 of 21 results
  TOP